Sex Differences in Neural Response to Cannabidiol
Latest Information Update: 26 Dec 2023
At a glance
- Drugs Cannabidiol (Primary)
- Indications Blepharospasm; Cerebral ischaemia; Dravet syndrome; Duchenne muscular dystrophy; Dyslipidaemias; Epilepsy; Heroin-related disorders; Infantile spasms; Lennox-Gastaut syndrome; Non-alcoholic fatty liver disease; Opioid-related disorders; Ovarian cancer; Parkinson's disease; Pervasive child development disorders; Rett syndrome; Schizophrenia; Sturge-Weber syndrome; Tuberous sclerosis; Type 2 diabetes mellitus; Ulcerative colitis
- Focus Pharmacodynamics
- 13 Jan 2023 Planned number of patients changed from 10 to 20.
- 13 Jan 2023 Planned End Date changed from 28 Feb 2023 to 28 Feb 2024.
- 13 Jan 2023 Planned primary completion date changed from 28 Feb 2023 to 28 Feb 2024.